Understanding and targeting osteoclastic activity in prostate cancer bone metastases

Current Molecular Medicine

Volumn 13, Issue 4, 2013, Pages 626-639

  Sottnik, J L ^a   Keller, E T ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Bisphosphonates; Bone microenvironment; Denosumab; IL 6; OPG; Osteoblast; Osteoclast; Prostate cancer; RANKL

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CATHEPSIN; DENOSUMAB; HYDROLASE; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE RELATED PROTEIN;

ACID SECRETION; ARTICLE; BONE METASTASIS; CANCER SURVIVAL; HUMAN; MALE; NONHUMAN; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; PROSTATE CANCER; QUALITY OF LIFE; TUMOR GROWTH;

BONE NEOPLASMS; BONE RESORPTION; HUMANS; INTERLEUKIN-6; MALE; OSTEOCLASTS; OSTEOPROTEGERIN; PARATHYROID HORMONE-RELATED PROTEIN; PROSTATIC NEOPLASMS; RANK LIGAND;

EID: 84876700548     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524011313040012     Document Type: Article

References (177)

1. Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 2000; 88(12 Suppl): 2989-2994.
2. Keller ET, Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 2004; 91(4): 718-729.
3. Roato I, D'Amelio P, Gorassini E, et al. Osteoclasts are active in bone forming metastases of prostate cancer patients. PLoS One 2008; 3(11): e3627.
4. Ignatoski KM, Friedman J, Escara-Wilke J, et al. Change in markers of bone metabolism with chemotherapy for advanced prostate cancer: interleukin-6 response is a potential early indicator of response to therapy. J Interferon Cytokine Res 2009; 29(2): 105-112.
5. Roland SI. Calcium studies in ten cases of osteoblastic prostatic metastasis. J Urol 1958; 79(2): 339-342.
6. Lynch CC, Hikosaka A, Acuff HB, et al. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 2005; 7(5): 485-496.
7. Menaa C, Kurihara N, Roodman GD. CFU-GM-derived cells form osteoclasts at a very high efficiency. Biochem Biophys Res Commun 2000; 267(3): 943-946.
8. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003; 423(6937): 337-342.
9. Roodman GD. Regulation of osteoclast differentiation. Ann NY Acad Sci 2006; 1068: 100-109.
10. Abu-Amer Y. IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB. J Clin Invest 2001; 107(11): 1375-1385.
11. Takahashi N, Maeda K, Ishihara A, Uehara S, Kobayashi Y. Regulatory mechanism of osteoclastogenesis by RANKL and Wnt signals. Front Biosci 2011; 16: 21-30.
12. Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer 2011; 11(6): 411-425.
13. Mundy GR, Yoneda T, Hiraga T. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment. Semin Oncol 2001; 28(2 Suppl 6): 35-44.
14. Whyte MP, Mumm S. Heritable disorders of the RANKL/OPG/RANK signaling pathway. J Musculoskelet Neuronal Interact 2004; 4(3): 254-267.
15. Brown JM, Corey E, Lee ZD, et al. Osteoprotegerin and rank ligand expression in prostate cancer. Urology 2001; 57(4): 611-616.
16. Castellano D, Sepulveda JM, Garcia-Escobar I, Rodriguez-Antolin A, Sundlov A, Cortes-Funes H. The role of RANK-ligand inhibition in cancer: the story of denosumab. Oncologist 2011; 16(2): 136-145.
17. Zhang J, Dai J, Qi Y, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001; 107(10): 1235-1244.
18. Ge C, Xiao G, Jiang D, et al. Identification and functional characterization of ERK/MAPK phosphorylation sites in the Runx2 transcription factor. J Biol Chem 2009; 284(47): 32533-32543.
19. Jang WG, Kim EJ, Bae IH, et al. Metformin induces osteoblast differentiation via orphan nuclear receptor SHP-mediated transactivation of Runx2. Bone 2011; 48(4): 885-93.
20. Akech J, Wixted JJ, Bedard K, et al. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 2010; 29(6): 811-821.
21. Daniell HW. Osteoporosis due to androgen deprivation therapy in men with prostate cancer. Urology 2001; 58(2 Suppl 1): 101-107.
22. Stege R. Potential side-effects of endocrine treatment of long duration in prostate cancer. Prostate Suppl 2000; 10: 38-42.
23. Vessella RL, Corey E. Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis. Clin Cancer Res 2006; 12(20 Pt 2): 6285s-6290s.
24. Higano C, Shields A, Wood N, Brown J, Tangen C. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. Urology 2004; 64(6): 1182-1186.
25. Lyritis GP, Georgoulas T, Zafeiris CP. Bone anabolic versus bone anticatabolic treatment of postmenopausal osteoporosis. Ann NY Acad Sci 2010; 1205: 277-283.
26. Halloran BP, Ferguson VL, Simske SJ, Burghardt A, Venton LL, Majumdar S. Changes in bone structure and mass with advancing age in the male C57BL/6J mouse. J Bone Miner Res 2002; 17(6): 1044-1050.
27. Salo J, Lehenkari P, Mulari M, Metsikko K, Vaananen HK. Removal of osteoclast bone resorption products by transcytosis. Science 1997; 276(5310): 270-273.
28. Stenbeck G, Horton MA. Endocytic trafficking in actively resorbing osteoclasts. J Cell Sci 2004; 117(Pt 6): 827-836.
29. Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet 2003; 4(8): 638-649.
30. Cackowski FC, Anderson JL, Patrene KD, et al. Osteoclasts are important for bone angiogenesis. Blood 2009; 115(1): 140-149.
31. Sottnik JL, Zhang J, Macoska JA, Keller ET. The PCa Tumor Microenvironment. Cancer Microenviron 2011; 4(3): 283-297.
32. Morrissey C, True LD, Roudier MP, et al. Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases. Clin Exp Metastasis 2008; 25(4): 377-388.
33. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144(5): 646-674.
34. Mizutani K, Sud S, Pienta KJ. Prostate cancer promotes CD11b positive cells to differentiate into osteoclasts. J Cell Biochem 2009; 106(4): 563-569.
35. Shiozawa Y, Pedersen EA, Havens AM, et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 2011; 121(4): 1298-1312.
36. Shiozawa Y, Pienta KJ, Taichman RS. Hematopoietic stem cell niche is a potential therapeutic target for bone metastatic tumors. Clin Cancer Res 2011; 17(17): 5553-5558.
37. Facchini G, Caraglia M, Morabito A, et al. Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial. Cancer Biol Ther 2011; 10(6): 543-548.
38. Huang CF, Lira C, Chu K, et al. Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblasts. Cancer Res 2010; 70(11): 4580-4589.
39. Sabbota AL, Kim HR, Zhe X, Fridman R, Bonfil RD, Cher ML. Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration. Cancer Res 2010; 70(13): 5558-5566.
40. Wang Q, Diao X, Sun J, Chen Z. Regulation of VEGF, MMP-9, and metastasis by CXCR4 in a prostate cancer cell line. Cell Biol Int 2011; 35(9): 897-904.
41. Hall CL, Dai J, van Golen KL, Keller ET, Long MW. Type I collagen receptor (alpha 2 beta 1) signaling promotes the growth of human prostate cancer cells within the bone. Cancer Res 2006; 66(17): 8648-8654.
42. Hall CL, Dubyk CW, Riesenberger TA, Shein D, Keller ET, van Golen KL. Type I collagen receptor (alpha2beta1) signaling promotes prostate cancer invasion through RhoC GTPase. Neoplasia 2008; 10(8): 797-803.
43. McCarthy EF. Genetic diseases of bones and joints. Semin Diagn Pathol 2011; 28(1): 26-36.
44. Bekes EM, Schweighofer B, Kupriyanova TA, et al. Tumor-Recruited Neutrophils and Neutrophil TIMP-Free MMP-9 Regulate Coordinately the Levels of Tumor Angiogenesis and Efficiency of Malignant Cell Intravasation. Am J Pathol 2011; 179(3): 1455-1470.
45. Tapia T, Ottman R, Chakrabarti R. LIM kinase1 modulates function of membrane type matrix metalloproteinase 1: implication in invasion of prostate cancer cells. Mol Cancer 2011; 10: 6.
46. Xu D, McKee CM, Cao Y, Ding Y, Kessler BM, Muschel RJ. Matrix metalloproteinase-9 regulates tumor cell invasion through cleavage of protease nexin-1. Cancer Res 2010; 70(17): 6988-6998.
47. Keller ET. The role of osteoclastic activity in prostate cancer skeletal metastases. Drugs Today (Barc) 2002; 38(2): 91-102.
48. Nemeth JA, Yousif R, Herzog M, et al. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 2002; 94(1): 17-25.
49. Hou P, Troen T, Ovejero MC, et al. Matrix metalloproteinase-12 (MMP-12) in osteoclasts: new lesson on the involvement of MMPs in bone resorption. Bone 2004; 34(1): 37-47.
50. Radding W, Williams JP, Hardy RW, et al. Calmodulin concentrated at the osteoclast ruffled border modulates acid secretion. J Cell Physiol 1994; 160(1): 17-28.
51. Terpos E. Biochemical markers of bone metabolism in multiple myeloma. Cancer Treat Rev 2006; 32 Suppl 1: 15-19.
52. Lalande A, Roux S, Denne MA, et al. Indapamide, a thiazide-like diuretic, decreases bone resorption in vitro. J Bone Miner Res 2001; 16(2): 361-370.
53. Lehenkari P, Hentunen TA, Laitala-Leinonen T, Tuukkanen J, Vaananen HK. Carbonic anhydrase II plays a major role in osteoclast differentiation and bone resorption by effecting the steady state intracellular pH and Ca2+. Exp Cell Res 1998; 242(1): 128-137.
54. Tuukkanen J, Vaananen HK. Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits bone resorption in vitro. Calcif Tissue Int 1986; 38(2): 123-125.
55. Farina C, Gagliardi S. Selective inhibition of osteoclast vacuolar H(+)-ATPase. Curr Pharm Des 2002; 8(23): 2033-2048.
56. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296(24): 2947-2953.
57. Coluzzi F, Di Bussolo E, Mandatori I, Mattia C. Bone metastatic disease: taking aim at new therapeutic targets. Curr Med Chem 2011; 18(20): 3093-3115.
58. Leto G, Sepporta MV, Crescimanno M, Flandina C, Tumminello FM. Cathepsin L in metastatic bone disease: therapeutic implications. Biol Chem 2010; 391(6): 655-664.
59. Miyauchi Y, Ninomiya K, Miyamoto H, et al. The Blimp1-Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis. J Exp Med 2010; 207(4): 751-762.
60. Sturge J, Caley MP, Waxman J. Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat Rev Clin Oncol 2011; 8(6): 357-368.
61. Tumminello FM, Flandina C, Crescimanno M, Leto G. Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications. Biomed Pharmacother 2008; 62(2): 130-135.
62. Podgorski I, Linebaugh BE, Koblinski JE, et al. Bone marrow-derived cathepsin K cleaves SPARC in bone metastasis. Am J Pathol 2009; 175(3): 1255-1269.
63. Brubaker KD, Vessella RL, True LD, Thomas R, Corey E. Cathepsin K mRNA and protein expression in prostate cancer progression. J Bone Miner Res 2003; 18(2): 222-230.
64. Troen BR. The regulation of cathepsin K gene expression. Ann NY Acad Sci 2006; 1068: 165-172.
65. Sottnik JL, Lori JC, Rose BJ, Thamm DH. Glycolysis inhibition by 2-deoxy-D: -glucose reverts the metastatic phenotype in vitro and in vivo. Clin Exp Metastasis 2011; 28(8): 865-875.
66. Amuthan G, Biswas G, Ananadatheerthavarada HK, Vijayasarathy C, Shephard HM, Avadhani NG. Mitochondrial stress-induced calcium signaling, phenotypic changes and invasive behavior in human lung carcinoma A549 cells. Oncogene 2002; 21(51): 7839-7849.
67. Amuthan G, Biswas G, Zhang SY, Klein-Szanto A, Vijayasarathy C, Avadhani NG. Mitochondria-to-nucleus stress signaling induces phenotypic changes, tumor progression and cell invasion. EMBO J 2001; 20(8): 1910-1920.
68. Duong LT. Therapeutic inhibition of cathepsin K[mdash]reducing bone resorption while maintaining bone formation. BoneKEy Rep. [doi:10.1038/bonekey.2012.67]. 2012; 1(5).
69. Dougall WC, Chaisson M. The RANK/RANKL/OPG triad in cancer-induced bone diseases. Cancer Metastasis Rev 2006; 25(4): 541-549.
70. Burgess TL, Qian Y, Kaufman S, et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 1999; 145(3): 527-538.
71. Lacey DL, Tan HL, Lu J, et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 2000; 157(2): 435-448.
72. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93(2): 165-176.
73. Matsuzaki K, Udagawa N, Takahashi N, et al. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem Biophys Res Commun 1998; 246(1): 199-204.
74. O'Brien EA, Williams JH, Marshall MJ. Osteoprotegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria. Biochem Biophys Res Commun 2000; 274(2): 281-290.
75. Tsurukai T, Udagawa N, Matsuzaki K, Takahashi N, Suda T. Roles of macrophage-colony stimulating factor and osteoclast differentiation factor in osteoclastogenesis. J Bone Miner Metab 2000; 18(4): 177-184.
76. Suzuki J, Ikeda T, Kuroyama H, et al. Regulation of osteoclastogenesis by three human RANKL isoforms expressed in NIH3T3 cells. Biochem Biophys Res Commun 2004; 314(4): 1021-1027.
77. Tat SK, Pelletier JP, Velasco CR, Padrines M, Martel-Pelletier J. New perspective in osteoarthritis: the OPG and RANKL system as a potential therapeutic target? Keio J Med 2009; 58(1): 29-40.
78. Lum L, Wong BR, Josien R, et al. Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzymelike protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem 1999; 274(19): 13613-13618.
79. Ikeda T, Kasai M, Suzuki J, et al. Multimerization of the receptor activator of nuclear factor-kappaB ligand (RANKL) isoforms and regulation of osteoclastogenesis. J Biol Chem 2003; 278(47): 47217-47212.
80. Miyazaki T, Tanaka S, Sanjay A, Baron R. The role of c-Src kinase in the regulation of osteoclast function. Mod Rheumatol 2006; 16(2): 68-74.
81. Takatsuna H, Asagiri M, Kubota T, et al. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1. J Bone Miner Res 2005; 20(4): 653-662.
82. Raju R, Balakrishnan L, Nanjappa V, et al. A comprehensive manually curated reaction map of RANKL/RANK-signaling pathway. Database (Oxford) 2011; 2011: bar021.
83. Bozec A, Bakiri L, Hoebertz A, et al. Osteoclast size is controlled by Fra-2 through LIF/LIF-receptor signalling and hypoxia. Nature 2008; 454(7201): 221-225.
84. Matsuo K, Owens JM, Tonko M, Elliott C, Chambers TJ, Wagner EF. Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation. Nat Genet 2000; 24(2): 184-187.
85. Armstrong AP, Miller RE, Jones JC, Zhang J, Keller ET, Dougall WC. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate 2008; 68(1): 92-104.
86. Inoue H, Nishimura K, Oka D, et al. Prostate cancer mediates osteoclastogenesis through two different pathways. Cancer Lett 2005; 223(1): 121-128.
87. Ibrahim T, Sacanna E, Gaudio M, et al. Role of RANK, RANKL, OPG, and CXCR4 Tissue Markers in Predicting Bone Metastases in Breast Cancer Patients. Clin Breast Cancer 2011; 11(6): 369-375.
88. Tan W, Zhang W, Strasner A, et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 2011; 470(7335): 548-553.
89. Wittrant Y, Theoleyre S, Chipoy C, et al. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta 2004; 1704(2): 49-57.
90. Won HY, Lee JA, Park ZS, et al. Prominent bone loss mediated by RANKL and IL-17 produced by CD4+ T cells in TallyHo/JngJ mice. PLoS One 2011; 6(3): e18168.
91. Yamada A, Takami M, Kawawa T, et al. Interleukin-4 inhibition of osteoclast differentiation is stronger than that of interleukin-13 and they are equivalent for induction of osteoprotegerin production from osteoblasts. Immunology 2007; 120(4): 573-579.
92. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med (Berl) 2001; 79(5-6): 243-253.
93. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12(9): 1260-1268.
94. Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 2010; 48(4): 677-692.
95. Zinonos I, Labrinidis A, Lee M, et al. Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo. J Bone Miner Res 2011; 26(3): 630-643.
96. Bateman TA, Dunstan CR, Ferguson VL, Lacey DL, Ayers RA, Simske SJ. Osteoprotegerin mitigates tail suspension-induced osteopenia. Bone 2000; 26(5): 443-449.
97. Chen H, Gilbert LC, Lu X, et al. A new regulator of osteoclastogenesis: Estrogen response element binding protein in bone. J Bone Miner Res 2011; 26(10): 2537-2547.
98. Zheng Y, Zhou H, Ooi LL, Snir AD, Dunstan CR, Seibel MJ. Vitamin D deficiency promotes prostate cancer growth in bone. Prostate 2011; 71(9): 1012-1021.
99. Fili S, Karalaki M, Schaller B. Therapeutic implications of osteoprotegerin. Cancer Cell Int 2009; 9: 26.
100. Kamiya N, Suzuki H, Endo T, et al. Significance of serum osteoprotegerin and receptor activator of nuclear factor kappaB ligand in Japanese prostate cancer patients with bone metastasis. Int J Clin Oncol 2011; 16(4): 366-372.
101. Santini D, Perrone G, Roato I, et al. Expression pattern of receptor activator of NFkappaB (RANK) in a series of primary solid tumors and related bone metastases. J Cell Physiol 2010; 226(3): 780-784.
102. Corey E, Brown LG, Kiefer JA, et al. Osteoprotegerin in prostate cancer bone metastasis. Cancer Res 2005; 65(5): 1710-1718.
103. Blanchard F, Duplomb L, Baud'huin M, Brounais B. The dual role of IL-6-type cytokines on bone remodeling and bone tumors. Cytokine Growth Factor Rev 2009; 20(1): 19-28.
104. Sims NA, Walsh NC. GP130 cytokines and bone remodelling in health and disease. BMB Rep 2010; 43(8): 513-523.
105. Taga T, Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 1997; 15: 797-819.
106. Libertini SJ, Chen H, Al-Bataina B, et al. The interleukin 6 receptor is a direct transcriptional target of E2F3 in prostate tumor derived cells. Prostate 2011; 72(6): 649-660.
107. Bishop KA, Meyer MB, Pike JW. A novel distal enhancer mediates cytokine induction of mouse RANKl gene expression. Mol Endocrinol 2009; 23(12): 2095-2110.
108. Duplomb L, Baud'huin M, Charrier C, et al. Interleukin-6 inhibits receptor activator of nuclear factor kappaB ligand-induced osteoclastogenesis by diverting cells into the macrophage lineage: key role of Serine727 phosphorylation of signal transducer and activator of transcription 3. Endocrinology 2008; 149(7): 3688-3697.
109. Itoh S, Udagawa N, Takahashi N, et al. A critical role for interleukin-6 family-mediated Stat3 activation in osteoblast differentiation and bone formation. Bone 2006; 39(3): 505-512.
110. Zhou H, Newnum AB, Martin JR, et al. Osteoblast/osteocyte-specific inactivation of Stat3 decreases load-driven bone formation and accumulates reactive oxygen species. Bone 2011; 49(3): 404-411.
111. Morrissey C, Lai JS, Brown LG, et al. The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells. Prostate 2010; 70(4): 412-424.
112. Axmann R, Bohm C, Kronke G, Zwerina J, Smolen J, Schett G. Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. Arthritis Rheum 2009; 60(9): 2747-2756.
113. Yoshitake F, Itoh S, Narita H, Ishihara K, Ebisu S. Interleukin-6 directly inhibits osteoclast differentiation by suppressing receptor activator of NF-kappaB signaling pathways. J Biol Chem 2008; 283(17): 11535-11540.
114. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 1999; 161(1): 182-187.
115. Corcoran NM, Costello AJ. Interleukin-6: minor player or starring role in the development of hormone-refractory prostate cancer? BJU Int 2003; 91(6): 545-553.
116. Cardillo MR, Ippoliti F. IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis. Anticancer Res 2006; 26(5A): 3409-3416.
117. Lu Y, Zhang J, Dai J, et al. Osteoblasts induce prostate cancer proliferation and PSA expression through interleukin-6-mediated activation of the androgen receptor. Clin Exp Metastasis 2004; 21(5): 399-408.
118. Singh S, Singh R, Sharma PK, et al. Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion. Cancer Lett 2009; 283(1): 29-35.
119. Kim SW, Kim JS, Papadopoulos J, et al. Consistent interactions between tumor cell IL-6 and macrophage TNF-alpha enhance the growth of human prostate cancer cells in the bone of nude mouse. Int Immunopharmacol 2011; 11(7): 862-872.
120. Inokuchi J, Lau A, Tyson DR, Ornstein DK. Loss of annexin A1 disrupts normal prostate glandular structure by inducing autocrine IL-6 signaling. Carcinogenesis 2009; 30(7): 1082-1088.
121. Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 2005; 41(16): 2502-2512.
122. Paule B, Terry S, Kheuang L, Soyeux P, Vacherot F, de la Taille A. The NF-kappaB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches? World J Urol 2007; 25(5): 477-489.
123. Smith PC, Keller ET. Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. Prostate 2001; 48(1): 47-53.
124. Giuliani N, Colla S, Rizzoli V. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL). Exp Hematol 2004; 32(8): 685-691.
125. Han JH, Choi SJ, Kurihara N, Koide M, Oba Y, Roodman GD. Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood 2001; 97(11): 3349-3353.
126. Pirih FQ, Michalski MN, Cho SW, et al. Parathyroid hormone mediates hematopoietic cell expansion through interleukin-6. PLoS One 2010; 5(10): e13657.
127. Sterling JA, Edwards JR, Martin TJ, Mundy GR. Advances in the biology of bone metastasis: how the skeleton affects tumor behavior. Bone 2011; 48(1): 6-15.
128. Toribio RE, Brown HA, Novince CM, et al. The midregion, nuclear localization sequence, and C terminus of PTHrP regulate skeletal development, hematopoiesis, and survival in mice. FASEB J 2010; 24(6): 1947-1957.
129. Liao J, McCauley LK. Skeletal metastasis: Established and emerging roles of parathyroid hormone related protein (PTHrP). Cancer Metastasis Rev 2006; 25(4): 559-571.
130. Mannstadt M, Juppner H, Gardella TJ. Receptors for PTH and PTHrP: their biological importance and functional properties. Am J Physiol 1999; 277(5 Pt 2): F665-75.
131. Burtis WJ, Wu T, Bunch C, et al. Identification of a novel 17,000-dalton parathyroid hormone-like adenylate cyclase-stimulating protein from a tumor associated with humoral hypercalcemia of malignancy. J Biol Chem 1987; 262(15): 7151-7156.
132. Kayamori K, Sakamoto K, Nakashima T, et al. Roles of interleukin-6 and parathyroid hormone-related peptide in osteoclast formation associated with oral cancers: significance of interleukin-6 synthesized by stromal cells in response to cancer cells. Am J Pathol 2010; 176(2): 968-980.
133. Bhatia V, Mula RV, Falzon M. 1,25-Dihydroxyvitamin D(3) regulates PTHrP expression via transcriptional, post-transcriptional and post-translational pathways. Mol Cell Endocrinol 2011; 342(1-2): 32-40.
134. Liu XH, Kirschenbaum A, Yao S, Levine AC. The role of the interleukin-6/gp130 signaling pathway in bone metabolism. Vitam Horm 2006; 74: 341-355.
135. Liu XH, Kirschenbaum A, Yao S, Levine AC. Interactive effect of interleukin-6 and prostaglandin E2 on osteoclastogenesis via the OPG/RANKL/RANK system. Ann NY Acad Sci 2006; 1068: 225-233.
136. Amizuka N, Karaplis AC, Henderson JE, et al. Haploinsufficiency of parathyroid hormone-related peptide (PTHrP) results in abnormal postnatal bone development. Dev Biol 1996; 175(1): 166-176.
137. Miao D, He B, Jiang Y, et al. Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. J Clin Invest 2005; 115(9): 2402-2411.
138. Asadi F, Farraj M, Sharifi R, Malakouti S, Antar S, Kukreja S. Enhanced expression of parathyroid hormone-related protein in prostate cancer as compared with benign prostatic hyperplasia. Hum Pathol 1996; 27(12): 1319-1323.
139. Lu Y, Xiao G, Galson DL, et al. PTHrP-induced MCP-1 production by human bone marrow endothelial cells and osteoblasts promotes osteoclast differentiation and prostate cancer cell proliferation and invasion in vitro. Int J Cancer 2007; 121(4): 724-733.
140. Mizutani K, Sud S, McGregor NA, et al. The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment. Neoplasia 2009; 11(11): 1235-1242.
141. Sun T, Mary LG, Oh WK, et al. Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a Caucasian cohort. Clin Cancer Res 2011; 17(6): 1546-1552.
142. Liao J, Li X, Koh AJ, et al. Tumor expressed PTHrP facilitates prostate cancer-induced osteoblastic lesions. Int J Cancer 2008; 123(10): 2267-2278.
143. Asadi FK, Kukreja SC, Boyer B, Valess AM, Cook JL. E1A oncogene expression inhibits PTHrP P3 promoter activity and sensitizes human prostate cancer cells to TNF-induced apoptosis. Int Urol Nephrol 2010; 42(4): 971-978.
144. DaSilva J, Gioeli D, Weber MJ, Parsons SJ. The neuroendocrine-derived peptide parathyroid hormone-related protein promotes prostate cancer cell growth by stabilizing the androgen receptor. Cancer Res 2009; 69(18): 7402-7411.
145. Liao J, Schneider A, Datta NS, McCauley LK. Extracellular calcium as a candidate mediator of prostate cancer skeletal metastasis. Cancer Res 2006; 66(18): 9065-73.
146. Tenta R, Sourla A, Lembessis P, Luu-The V, Koutsilieris M. Bone microenvironment-related growth factors, zoledronic acid and dexamethasone differentially modulate PTHrP expression in PC-3 prostate cancer cells. Horm Metab Res 2005; 37(10): 593-601.
147. Pettway GJ, Meganck JA, Koh AJ, Keller ET, Goldstein SA, McCauley LK. Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation. Bone 2008; 42(4): 806-818.
148. Lipton A, Goessl C. Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis. Bone 2011; 48(1): 96-99.
149. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377(9768): 813-822.
150. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29(9): 1125-1132.
151. Weintraub B. Trials define anti-tumor effects of anti-resorptive agents: denosumab ahead of zoledronate 2 to 1. BioDrugs 2011; 25(2): 135-138.
152. Aljumaily R, Mathew P. Optimal management of bone metastases in prostate cancer. Curr Oncol Rep 2011; 13(3): 222-230.
153. Fizazi K, Bosserman L, Gao G, Skacel T, Markus R. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. J Urol 2009; 182(2): 509-515; discussion 15-16.
154. Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009; 27(10): 1564-1571.
155. Weinstein RS, Chen JR, Powers CC, et al. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest 2002; 109(8): 1041-1048.
156. Hussein O, Tiedemann K, Komarova SV. Breast cancer cells inhibit spontaneous and bisphosphonate-induced osteoclast apoptosis. Bone 2011; 48(2): 202-211.
157. Hung TT, Chan J, Russell PJ, Power CA. Zoledronic acid preserves bone structure and increases survival but does not limit tumour incidence in a prostate cancer bone metastasis model. PLoS One 2011; 6(5): e19389.
158. Quinn JE, Brown LG, Zhang J, Keller ET, Vessella RL, Corey E. Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. Prostate Cancer Prostatic Dis 2005; 8(3): 253-259.
159. Sonpavde G, Sternberg CN. Contemporary management of metastatic castration-resistant prostate cancer. Curr Opin Urol 2011; 21(3): 241-247.
160. Prevarskaya N, Skryma R, Shuba Y. Ca2+ homeostasis in apoptotic resistance of prostate cancer cells. Biochem Biophys Res Commun 2004; 322(4): 1326-1335.
161. Prevarskaya N, Skryma R, Shuba Y. Calcium in tumour metastasis: new roles for known actors. Nat Rev Cancer 2011; 11(8): 609-618.
162. Li X, Liao J, Park SI, et al. Drugs which inhibit osteoclast function suppress tumor growth through calcium reduction in bone. Bone 2011; 48(6): 1354-1361.
163. Annabi B, Bouzeghrane M, Currie JC, et al. Inhibition of MMP-9 secretion by the anti-metastatic PSP94-derived peptide PCK3145 requires cell surface laminin receptor signaling. Anticancer Drugs 2006; 17(4): 429-438.
164. Chinni SR, Sivalogan S, Dong Z, et al. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. Prostate 2006; 66(1): 32-48.
165. Li Y, Kucuk O, Hussain M, Abrams J, Cher ML, Sarkar FH. Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer. Cancer Res 2006; 66(9): 4816-4825.
166. Wu KJ, Zeng J, Zhu GD, et al. Silibinin inhibits prostate cancer invasion, motility and migration by suppressing vimentin and MMP-2 expression. Acta Pharmacol Sin 2009; 30(8): 1162-1168.
167. Singh RP, Raina K, Deep G, Chan D, Agarwal R. Silibinin suppresses growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase 1/2 and inhibition of signal transducers and activators of transcription signaling. Clin Cancer Res 2009; 15(2): 613-621.
168. Barrett JM, Rovedo MA, Tajuddin AM, et al. Prostate cancer cells regulate growth and differentiation of bone marrow endothelial cells through TGFbeta and its receptor, TGFbetaRII. Prostate 2006; 66(6): 632-650.
169. Niu Y, Altuwaijri S, Lai KP, et al. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci USA 2008; 105(34): 12182-7.
170. Pratap J, Akech J, Wixted JJ, et al. The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss. Mol Cancer Ther 2010; 9(12): 3210-3220.
171. Lamoureux F, Thomas C, Yin MJ, et al. A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis. Clin Cancer Res 2011; 17(8): 2301-2313.
172. Culig Z, Steiner H, Bartsch G, Hobisch A. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 2005; 95(3): 497-505.
173. Wallner L, Dai J, Escara-Wilke J, et al. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Res 2006; 66(6): 3087-3095.
174. Karkera J, Steiner H, Li W, et al. The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. Prostate 2011; 71(13): 1455-1465.
175. Voorhees PM, Chen Q, Kuhn DJ, et al. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin Cancer Res 2007; 13(21): 6469-6478.
176. Wang P, Zou X, Huang J, Zhang T. Gadolinium inhibits prostate cancer PC3 cell migration and suppresses osteoclast differentiation in vitro. Cell Biol Int 2011; 35(11): 1159-1167.
177. Lee JW, Iwahashi A, Hasegawa SI, et al. Coptisine inhibits RANKL-induced NF-kappaB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells. J Nat Med 2011; 66(1): 8-16.